RE:RE:RE:RE:RE:New base $2
I've pondered that same thing but have come to the conculsion that the reaction will not be tempered on account of the fact that 1) unless an investor is in the know, they don't know what a portal vein injection is and all they see is "Insulin Independent" And 2) it is still significant that the pouch with, quote, "a marginal dose of islets" in the portal vein is producing insulin independence. If that is the functional cure, then it is still a vast improvement on the vanilla edmonton protocol. Marginal doses of islets i would assume would be less dangerous. And the edmonton protocol on its own does not 100% gaurantee insulin independence. But if the pouch + edmonton protocol does, well then shoot, they did it. It would mean that there is an option for every type 1 diabetic to become insulin independent. Think about it, perhaps a large dose of islets in the portal vein has issues with engrafment. Maybe only half the cells engraft because they are too clumped up on eachother. But the pouch takes the load off, does half the battle, and then a small thin, highly engraftable, layer of islets in the portal vein does the rest. Its very significant. But still raises the question of of the pouch + portal vein produces the same result 100% of the time. 3) I think we can all agree that the share price move was stunted last january through various avoidable circumstances. 1st with the PP at $1.20 with the supposed participants shorting the stock and the $1.20 valuation screaming at investors while they pay $2.50. And that doug lowe bs price target that was below the current share price when it came out. These should not be a factor this time.